Catalyst Calendar

Fri, Sep 4, 2026

1 updates

4:41 PM

Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)

CARLSBAD, Calif. --(BUSINESS WIRE)--Sep. 4, 2026-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner Novartis today announced that the pelacarsen Phase 3 Lp(a)HORIZON study, a pioneering cardiovascular outcomes trial, did not meet its primary endpoint of reducing the risk of cardiovascular events,

Trial Results • Phase 3Phase 3 topline results Fri, Sep 4, 2026ionis.com

Thu, Sep 3, 2026

2 updates

IONS

7:47 PM

ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients

- Provides a clinically meaningful impact on motor function and a favorable impact on other symptoms seen in AxD, an ultra-rare, progressive and often fatal neurological disorder - - Priority Review Voucher (PRV) awarded in conjunction with approval - - ZANVASTRO marks Ionis’ first independent

ionis.com

IONS

7:05 AM

Ionis to present at upcoming investor conferences

CARLSBAD, Calif. --(BUSINESS WIRE)--Sep. 3, 2026-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: 21 st Annual Wells Fargo Healthcare Conference on Thursday, September 10, 2026 Morgan Stanley 24 th

ionis.com

Mon, Aug 24, 2026

1 updates

IONS

8:47 AM

Ionis partner GSK announces Hibsago (bepirovirsen) approved in Japan as first and only functional cure for chronic hepatitis B

Ionis partner GSK announces Hibsago (bepirovirsen) approved in Japan as first and only functional cure for chronic hepatitis B August 24, 2026 – Ionis partner GSK today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Hibsago (bepirovirsen) as a functional cure for

ionis.com

Thu, Aug 20, 2026

1 updates

IONS

7:00 AM

Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026

CARLSBAD, Calif. --(BUSINESS WIRE)--Aug. 20, 2026-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that new data in the management of severe hypertriglyceridemia (sHTG) will be presented at the European Society of Cardiology (ESC) Congress 2026, taking place August 28 – 31 in Munich.

Presentation / Abstract • Phase 3ESC Congress oral presentation Fri, Aug 28, 2026, 8:33 AM CESTionis.com

Wed, Jul 29, 2026

2 updates

IONS

7:05 AM

Ionis announces Dr. Frank Bennett, chief scientific officer, to retire

CARLSBAD, Calif. --(BUSINESS WIRE)--Jul. 29, 2026-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that Frank Bennett, Ph.D., executive vice president and chief scientific officer, will retire effective February 2027. “As a founding scientist, Frank has been instrumental in shaping

ionis.com

IONS

7:00 AM

Ionis reports second quarter 2026 financial results and highlights progress on key programs

- TRYNGOLZA ® (olezarsen) demonstrating early sHTG launch momentum, underscoring multi-billion-dollar revenue potential in large patient population – - Completed enrollment in Phase 3 REVEAL trial in Angelman syndrome - - On track to achieve 2026 financial guidance - CARLSBAD, Calif.

Presentation / Abstract • Phase 1ESC abstract release Sat, Aug 1, 2026ionis.com

Wed, Jul 15, 2026

1 updates

IONS

7:05 AM

Ionis to hold second quarter 2026 financial results webcast

Webcast scheduled for Wednesday, July 29 at 8:30 a.m. Eastern Time CARLSBAD, Calif. --(BUSINESS WIRE)--Jul. 15, 2026-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, July 29 at 8:30 a.m. Eastern Time to discuss its second quarter 2026

ionis.com

Tue, Jul 14, 2026

1 updates

IONS

9:16 AM

Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease

- Clinical outcomes: Diranersen demonstrated efficacy across all studied doses at 18 months, with consistent results across multiple prespecified clinical endpoints; the 60 mg dose showed the strongest response with slowing of clinical decline on the cognitive endpoints—42% on ADAS-Cog13 and 50% on

Presentation / Abstract • Phase 2AAIC presentation Tue, Jul 14, 2026ionis.com

Mon, Jul 13, 2026

1 updates

IONS

7:00 AM

Ionis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndrome

CARLSBAD, Calif. --(BUSINESS WIRE)--Jul. 13, 2026-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the first participant has been dosed in the Phase 1-2 ASCEND study of ION337, an investigational RNA-targeted medicine for people living with Dravet syndrome, a rare, severe and

Trial Start • Phase 1/2Trial initiation Mon, Jul 13, 2026ionis.com

Thu, Jul 9, 2026

1 updates

IONS

2:00 AM

Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy

– Study missed primary endpoint of composite outcome of cardiovascular (CV) mortality and recurrent CV events; in a pre-specified subgroup analysis, a nominally significant result was observed with eplontersen monotherapy – – Favorable safety profile consistent with previous results – CARLSBAD,

Trial Results • Phase 3Results event Thu, Jul 9, 2026ionis.com

Mon, Jul 6, 2026

1 updates

IONS

7:00 AM

Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome

- Topline data from REVEAL anticipated in 2H 2027 - CARLSBAD, Calif. --(BUSINESS WIRE)--Jul. 6, 2026-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has completed enrollment in the pivotal cohort (Cohort 1) of the global Phase 3 REVEAL study evaluating obudanersen (ION582), an

Enrollment • Phase 3Enrollment milestone Mon, Jul 6, 2026ionis.com

Thu, Jun 25, 2026

1 updates

IONS

2:59 AM

Ionis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S.

- Recordati brings deep rare disease expertise and proven capabilities in commercialization, access and country-specific regulatory environments - - Ionis to independently commercialize zilganersen in the U.S. assuming FDA approval - CARLSBAD, Calif. --(BUSINESS WIRE)--Jun.

ionis.com

Wed, Jun 24, 2026

1 updates

IONS

2:37 PM

TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)

– Proven to deliver significant and robust triglyceride reductions – – Only treatment for sHTG indicated to reduce the risk of acute pancreatitis – – Ionis’ first independent commercial launch in a prevalent condition – – Ionis to host webcast today at 3:30 p.m. ET – CARLSBAD, Calif.

ionis.com